72RO Palbociclib and anastrozole for patients with estrogen receptor-positive recurrent or metastatic endometrial cancer
Year: 2026
Type: article
Abstract: Current standard of care for metastatic or recurrent endometrial cancer (EC) is chemo-immunotherapy, which is not curative, may be poorly tolerated and has significant financial toxicity, especially for low-middle income countries. For low-grade histologies hormonal therapy (HT) may have milder adverse events with similar efficacy.
Source: ESMO Open
Authors: C. Nagpal, S. Khurana, P.S. Malik, S. Singhal, M. Ray, B. Bansal, S. Mathur, R. Pramanik
Language: English
Subfield: Obstetrics and Gynecology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7167077192
FWCI:
Cites:
Cited by:
Related to: